EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Treatment Standards for Metastatic Uveal Melanoma

Paweł Rogala, Anna M Czarnecka iD, Monika Dudzisz-Śledź, Anna Dawidowska, Kacper J Piwowarek, Piotr Rutkowski iD

Cancers · 31.01.2026 · 18 (3) · 475

DOI: 10.3390/cancers18030475 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.01.2026. Verfasst von Paweł Rogala und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, most commonly arising in the choroid. Its development is associated with phenotypic characteristics, ultraviolet radiation, and germline or somatic genetic alterations. Despite progress in diagnostics and local therapies, UM remains characterized by high metastatic risk and poor overall prognosis. This review aimed to summarize current knowledge on epidemiology, clinical features, genetic background, prognostic factors, and therapeutic approaches in metastatic UM.

Methods

A structured literature review was conducted to evaluate epidemiological trends, genetic alterations, prognostic markers, clinical presentation, and therapeutic strategies. The results of different systemic treatments were analyzed, with special attention to liver-directed interventions and emerging systemic therapies.

Results

The incidence of UM in Europe increases with latitude, ranging from two per million in the southern regions to more than eight per million in the North. The median age at diagnosis is 62 years, and most cases are detected incidentally during ophthalmological examinations due to nonspecific symptoms. Some genetic alterations serve as important prognostic indicators. Local treatment consists of globe-preserving procedures, including radiation therapy, surgery, laser therapy, or enucleation, with failure rates between 6.15% and 20.8%. Up to 70% of patients develop distant metastases, predominantly in the liver. Metastatic UM (mUM) carries a poor prognosis, with overall survival ranging from 3 to 30 months. Liver-directed therapies, particularly surgical resection, provide the most favorable outcomes. Systemic therapies demonstrate limited efficacy; however, tebentafusp has shown an overall survival benefit in HLA-A*02:01 (human leukocyte antigen A*02:01)-positive patients.

Conclusions

UM is a rare but aggressive malignancy with limited treatment options once metastatic. Liver-directed strategies remain the mainstay of management, while novel systemic approaches, including tebentafusp, represent promising advances. Further research is required to improve survival and expand therapeutic opportunities.

Schlagwörter

Stichwörter der Autor:innen

anti-CTLA4anti-PD1immunotherapyliver-directed therapymetastasestebentafuspuveal melanoma

Autor:innen und Institutionen

  • Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Department of Outpatient Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland.
  • Early Phase Clinical Trials Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.

ORCID-Profile: Anna M Czarnecka, Piotr Rutkowski

Zitieren

APA

Rogala, P., Czarnecka, A. M., Dudzisz-Śledź, M., Dawidowska, A., Piwowarek, K. J., & Rutkowski, P. (2026). Current Treatment Standards for Metastatic Uveal Melanoma. Cancers, 18(3), 475. https://doi.org/10.3390/cancers18030475

Vancouver

Rogala P, Czarnecka AM, Dudzisz-Śledź M, Dawidowska A, Piwowarek KJ, Rutkowski P. Current Treatment Standards for Metastatic Uveal Melanoma. Cancers. 2026;18(3):475. doi:10.3390/cancers18030475

BibTeX
@article{Rogala2026,
  author = {Rogala, Paweł and Czarnecka, Anna M and Dudzisz-Śledź, Monika and Dawidowska, Anna and Piwowarek, Kacper J and Rutkowski, Piotr},
  title = {Current Treatment Standards for Metastatic Uveal Melanoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {475},
  doi = {10.3390/cancers18030475}
}
Kostenlos starten →